

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Lilian Alcaraz et al.	Art Unit	: 1625
Serial No.	: 10/587,633	Examiner	: Celia Chang
Filed	: July 28, 2006	Conf. No.	: 2655
Title	: NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR)		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 3.73(b) AND 1.321(b)

Pursuant to 37 C.F.R. § 3.73(b), AstraZeneca AB, a Swedish corporation, certifies that it is the assignee of the entire right, title, and interest in the above-referenced application, U.S. Application No. 10/587,633, by virtue of an assignment from the inventors of U.S. Application No. 10/587,633 to AstraZeneca AB. The assignment from the inventors of U.S. Application No. 10/587,633 to AstraZeneca AB was recorded in the Patent and Trademark Office on July 28, 2006 at Reel 018131, Frame 0721.

AstraZeneca AB also certifies that it is the assignee of the entire right, title, and interest of U.S. Patent No. 7,709,500, by virtue of an assignment from the inventors of U.S. Patent No. 7,709,500 to AstraZeneca AB. The assignment from the inventors of U.S. Patent No. 7,709,500 to AstraZeneca AB was recorded in the Patent and Trademark Office on March 30, 2005 at Reel 015974, Frame 0629.

The undersigned has reviewed all the documents in the chain of title of U.S. Application No. 10/587,633 and to the best of undersigned's knowledge and belief, AstraZeneca AB is the owner of the entire right, title, and interest in U.S. Application No. 10/587,633.

The undersigned is empowered to act on behalf of the assignee.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal part of any patent granted on U.S. Application No. 10/587,633 which would extend beyond the expiration date of the full statutory term, including statutory extensions thereof, of U.S. Patent No. 7,709,500, except to the extent that the term of any patent granted on U.S. Application No. 10/587,633 might be extended pursuant to the Drug

CERTIFICATE OF MAILING BY EFS-WEB FILING

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: December 1, 2010.

Price Competition and Patent Term Restoration Act of 1984 (35 USC §156), and hereby agrees that any patent so granted on U.S. Application No. 10/587,633 shall be enforceable only for and during such period that it and U.S. Patent No. 7,709,500, are commonly owned, this agreement to run with any patent granted on U.S. Application No. 10/587,633 and to be binding upon the grantee, its successors or assigns.

AstraZeneca AB does not disclaim any terminal part of any patent granted on U.S. Application No. 10/587,633 prior to the expiration date of the full statutory term of U.S. Pat. No. 7,709,500, including statutory extensions thereof, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its full statutory term, including statutory extensions thereof.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Applicant : Lilian Alcaraz et al.
Serial No. : 10/587,633
Filed : July 28, 2006
Page : 3 of 3

Attorney's Docket No.: 06275-0518US1 / 101318-1P
US/R&I

The fee in the amount of \$140 for the required fee pursuant to 37 C.F.R. § 1.20(d) is being paid concurrently herewith on the Electronic Filing System (EFS) by way of a Deposit Account authorization. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-0518US1 / 101318-1P US/R&I.

Respectfully submitted,

Date: December 1, 2010

/John T. Kendall/
John T. Kendall, Ph.D.
Reg. No. 50,680

Customer Number 26164
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22536932.doc